Liver disease as a major cause of death among HIV infected patients: Role of hepatitis C and B viruses and alcohol

Journal of Hepatology

Volumn 42, Issue 6, 2005, Pages 799-805

  Salmon Ceron, Dominique ^a   Lewden, Charlotte ^b   Morlat, Philippe ^b,c   Bévilacqua, Sibylle ^d   Jougla, Eric ^b   Bonnet, Fabrice ^b,c   Héripret, Laurence ^e   Costagliola, Dominique ^b   May, Thierry ^d   Chêne, Geneviève ^b  

^a Cochin Hospital ^*  (France)

^b INSERM   (France)

^c HÔPITAL SAINT ANDRÉ   (France)

^d CHU NANCY BRABOIS   (France)

^e CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

AIDS; Causes of death; HAART; Hepatitis B; Hepatitis C; Hepatocellular carcinoma; HIV infection; Mortality

Indexed keywords

ALCOHOL; CD4 ANTIGEN; HEPATITIS B SURFACE ANTIGEN;

ADULT; ARTICLE; CONTROLLED STUDY; DEATH; DISEASE ASSOCIATION; FEMALE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CELL CARCINOMA; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; ANTIVIRAL AGENTS; CAUSE OF DEATH; COMORBIDITY; DATA COLLECTION; FEMALE; FRANCE; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER DISEASES, ALCOHOLIC; MALE; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES;

EID: 17044415559     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2005.01.022     Document Type: Article

References (26)

1. F.J. Palella, K.M. Delaney, A.C. Moorman, M.O. Loveless, J. Fuhrer, and G.A. Satten Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection N Engl J Med 338 1998 853 860
2. Cascade Collaboration Survival after introduction of HAART in people with known duration of HIV-1 infection Lancet 355 2000 1158 1159
3. K.E. Sherman, S. Freeman, S. Harrison, and L. Andron Prevalence of antibodies to hepatitis C virus in patients infected with the human immunodeficiency virus J Infect Dis 163 1991 414 415
4. D. Salmon-Céron, P. Gouëzel, E. Delarocque-Astagneau, L. Piroth, P. Dellamonica, and P. Marcellin Hospitalized HIV-HCV co-infected patients. A French national survey made in June 2001 Med Mal Infect 33 2003 78 83
5. F. Saillour, F. Dabis, M. Dupon, D. Lacoste, P. Trimoulet, and P. Rispal Prevalence and determinants of antibodies to hepatitis C virus and markers for hepatitis B virus infection in patients with HIV infection in Aquitaine Br Med J 313 1996 461 464
6. P.H. Hayashi, N. Flynn, S.A. McCurdy, I.K. Kuramoto, P.V. Holland, and J.B. Zeldis Prevalence of hepatitis C virus antibodies among patients infected with human immunodeficiency virus J Med Virol 33 1991 177 180
7. C.L. Thio, E.C. Seaberg, R. Skolasky, J. Phair, B. Visscher, and A. Munoz HIV-1, hepatitis B virus, and risk of liver-related mortality in the multicenter AIDS cohort study (MACS) Lancet 360 2002 1921 1926
8. B. Cribier, D. Rey, C. Schmitt, J.M. Lang, A. Kim, and F. Stoll-Keller High hepatitis viremia and impaired antibody response in patients co-infected with HIV AIDS 9 1995 1131 1136
9. B. Soto, A. Sanchez-Quijano, L. Rodrigo, J.A. Del Olmo, M. Garcia-Bengoechea, and J. Hernandez-Quero Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis J Hepatol 26 1997 1 5
10. Y. Benhamou, M. Bochet, V. Di Martino, F. Charlotte, F. Azria, and A. Coutelier Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients Hepatology 30 1999 1054 1058
11. M. Puoti, A. Spinetti, A. Ghezzi, F. Donato, S. Zaltron, and V. Putzolu Mortality from liver disease in patients with HIV infection: a cohort study J Acquir Immune Defic Syndr 24 2000 211 217
12. S.C. Darby, D.W. Ewart, P.L.F. Giangrande, R.J. Spooner, C.R. Rizza, and G.M. Dusheiko Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C Lancet 350 1997 1425 1431
13. H.K. Monga, M.C. Rodriguez-Barradas, K. Breaux, K. Khattak, C.L. Troisi, and M. Velez Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection Clin Infect Dis 33 2001 240 247
14. S. Conti, M. Masocco, P. Pezzotti, V. Toccaceli, M. Vichi, and R. Crialesi Excess mortality from liver disease and other non-AIDS-related diseases among HIV-infected individuals in Italy J Acquir Immune Defic Syndr 29 2002 105 107
15. E. Rosenthal, M. Poirée, C. Pradier, C. Perronne, D. Salmon-Ceron, and E. Geffray Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 Study) AIDS 17 2003 1 7
16. V. Soriano, L. Martin-Carbonero, J. Garcia-Samaniego, and M. Puoti Mortality due to viral liver disease among patients infected with HIV Clin Infect Dis 32 2001 492 497
17. Lewden C, Bévilacqua S, Bonnet F, Héripret L, Salmon D, Morlat P, et al. Causes of death in HIV-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol [in press].
18. International Classification of Diseases. Tenth Revision ed. Geneva: World Health Organization; 1993.
19. Centers for Disease Control and Prevention 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults MMWR 41 1992 1 19
20. H.B. El-Serag Hepatocellular carcinoma and hepatitis C in the United States Hepatology 36 2002 S74 S83
21. M. Colombo, and A. Sangiovanni Etiology, natural history and treatment of hepatocellular carcinoma Antiviral Res 60 2003 145 150
22. R.T. Chung, J. Andersen, P. Volberding, G.K. Robbins, T. Liu, and K.E. Sherman Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons N Engl J Med 351 2004 451 459
23. F. Carrat, F. Bani-Sadr, S. Pol, E. Rosenthal, F. Lunel-Fabiani, and A. Benzekri Final Results of ANRS HC02 RIBAVIC: a randomized trial of pegylated-interferon alfa-2b plus ribavirin vs interferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV co-infected patients J AM Med Assoc 292 2004 2839 2913
24. F.J. Torriani, M. Rodriguez-Torres, J.K. Rockstroh, E. Lissen, J. Gonzalez-Garcia, and A. Lazzarin Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients N Engl J Med 351 2004 438 450
25. M.P. Manns, J.G. Mac Hutchison, and S.C. Gordon Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial Lancet 358 2001 958 965
26. A. Alberti, N. Clumeck, S. Collins, W. Gerlich, J. Lundgren, and G. Palù Short statement of the First European Consensus Conference on the Treatment of Chronic Hepatitis B and C in HIV Co-Infected patients J Hepatol 42 2005 615 624